Manali Bhave, MD

• A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

  • Phase

    I
  • Conditions

    HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
  • Location

    Winship Cancer Institute

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

  • Phase

    II
  • Conditions

    Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
  • Location

    Winship Cancer Institute

• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

  • Phase

    III
  • Conditions

    Breast Neoplasms
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Grady Health System, Winship Cancer Institute

• Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

  • Phase

    I
  • Conditions

    Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

  • Phase

    N/A
  • Conditions

    Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Early Stage Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
  • Location

    Emory University Hospital Midtown, Winship Cancer Institute

• Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

  • Phase

    II
  • Conditions

    Breast Cancer
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Winship Cancer Institute

• DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

  • Phase

    II
  • Conditions

    Breast Cancer
  • Location

    Emory University Hospital Midtown, Emory Saint Joseph's Hospital, Grady Health System, Winship Cancer Institute

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.

Clinical breast cancer

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States.

Breast cancer research and treatment

Prospective investigation of amino acid transport and PSMA-targeted positron emission tomography for metastatic lobular breast carcinoma.

European journal of nuclear medicine and molecular imaging

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.

Breast cancer research and treatment

Pharmacological suppression of the OTUD4/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers.

The Journal of clinical investigation

Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy.

Clinical breast cancer

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Annals of oncology : official journal of the European Society for Medical Oncology

A Discordant Pattern of Uptake on 68 Ga-PSMA PET/CT Versus 18 F-Fluciclovine PET/CT in Radiation-Induced Hepatitis : Implications for Early Postradiotherapy Imaging-Based Response Assessment.

Clinical nuclear medicine

Racial Disparities in Clinical Outcomes on Investigator-Initiated Breast Cancer Clinical Trials at an Urban Medical Center.

Clinical breast cancer

A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-Fluciclovine, 68Ga-PSMA, and 18F-FDG in the Uterus and Adnexa.

Clinical nuclear medicine

Spatially variant immune infiltration scoring in human cancer tissues.

NPJ precision oncology

Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.

Translational lung cancer research

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Cancer treatment reviews

05/25/2025

Dr Behave was very patient, observant to your concerns, she took notes as you spoke to her, she asked questions about other health issues concerning you & talked about them briefly with you. She was very informative & it was important to her that I understood that treatment would be based solely on my particular "journey". I left with Radiation free fears after speaking with her. I Love how she conditioners herself part of a Team" of Dr/s, It made me feel Emory cares very much about the success to keep women alive diagnosed with cancer.

05/15/2025

Dr. Bhave is extremely knowledgeable and helpful. She had thoroughly reviewed my history from the records sent from MS. She asked questions, provided answers and context. Listened intently answered my questions and included her nurse and nurse practitioner in the appointment. She was Outstanding!!!

05/05/2025

When you're going through cancer, sometimes you need a supporting medical team to help. You understand the different changes that happens in your body. I can say without a doubt that Dr. Bhave and team of staffers are so caring and supportive Thank you for your support and dedication to your profession

04/24/2025

As I said Dr bhave is outstanding . Knowledgeable , sensitive and very caring. I was clearly upset from my horrible experience getting my mammogram . She was most sensitive.

04/19/2025

Good

04/15/2025

She is very considerate, a good listener and seems very thorough with broad knowledge of treatment options and pros and cons.

02/09/2025

My doctor, Dr. Bhave is amazingly attentive, empathetic, sympathetic as a human being, and highly competent in her field with unmatched bedside manner. I've been seeing her for almost four years now and I feel like she single-handedly extended my lifespan with her treatments and the appropriate medications she prescribed for me. I cannot thank her enough. She is a treasure to the establishment.

02/06/2025

Bhave is wonderful, check in system not so good this time with table around the corner involved.

01/19/2025

Dr. Bhave is just a wonderful person and Dr..

01/04/2025

Dr. Bhave is wonderful! She looks you in the eye, explaines everything thoroughly, and answers all of my questions.

12/26/2024

So blessed to have a physician of such compassion and expertise!

12/08/2024

Dr. Bhave is a knowledgeable physician who is cordial and sensitive to my concerns.

12/05/2024

Absolutely recommend

11/23/2024

Dr. Bhave is awesome as always!!

11/09/2024

Dr. Bhave is THE BEST!! I'll go to her as long as she stays at Emory.

11/09/2024

Dr. Bhave's bedside manners are caring and very detailed.

11/02/2024

Good

09/27/2024

Dr Bhave is an awesome doctor she has genuine care for you.

09/27/2024

Dr, Bhave ( Outstanding Medical Professional) Kayla / NP ( Highly Skilled / Outstanding ) Highly recommend to others.

09/22/2024

Good

09/14/2024

They took their time and answered all of my questions- such a gift.

08/31/2024

They took their time with me. Answered all of my questions.

08/22/2024

Dr. Behave is very compassionate and helpful.

08/17/2024

Love Dr Bhave and nurses

08/17/2024

Dr. Bhave is excellent.

07/06/2024

Excellent team: Dr Bhavi and staff,Bobbie, and Monique.

06/22/2024

Dr Bhave apologized for lateness of meeting and I really appreciated the effort and consideration. She listened to my suggestions and was considerate of all my ideas for treatment while I wanted to be cautious of side effects. I also wanted to suggest a more Natural Homeopathic form of treatment to avoid any problems or complications from pharmaceutical drug side-effects because of my age and medical conditions. I was never informed that Anastrozole increased complications with Arthritis. I suffer from Chronic Arthritis and want to avoid it at all costs!

06/16/2024

I am very fortunate I believe to have been assigned to Dr Bhave. Her care is amazing!!!